Intelligent Bio Solutions Inc.

INBS Nasdaq SEC CIK 1725430
Follow Intelligent Bio Solutions Weekly email: filings, results

Financials

Reported figures only · latest: Q1 2027 USD · US GAAP
Revenue, last quarter $1.4M +25.2% vs same quarter last year
Net income −$2.7M +10.9% vs same quarter last year
EPS, diluted −$0.86 +75.4% vs same quarter last year
Operating cash flow −$2.8M +3.3% vs same quarter last year
Revenue by quarter
$607.5K
$728.9K
$843.9K
$1.1M
$896.8K
$1.1M
$1.1M
$1.4M
Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$15M−$10M−$5M$0$5MFY19FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearRevenueNet income
FY26$4.2M−$12.5M
FY25$3.1M−$10.6M
FY24$3.1M−$10.2M
FY23$1.3M−$10.6M
FY22$437.1K−$8.3M
FY21$2M−$7M
FY20$188.7K−$3.2M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%500%FY19FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearGross marginOperating marginNet margin
FY2648.6%−299.1%−295.8%
FY2540.8%−349.8%−347.4%
FY2445.8%−330.5%−327.5%
FY2326%−1002.1%−845.9%
FY22-−1907.1%−1900.1%
FY21-−281.4%−355.3%
FY20-−1513.7%−1676.2%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearFree cash flow
FY26−$12.1M
FY25−$9.9M
FY24−$9.8M
FY23-
FY22-
FY21-
FY20-
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Intelligent Bio Solutions
  • Healthcare median
−2000%−1500%−1000%−500%0%FY19FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearIntelligent Bio SolutionsHealthcare median
FY26−295.8%−11.1%
FY25−347.4%−30.6%
FY24−327.5%−47%
FY23−845.9%−58%
FY22−1900.1%−80.4%
FY21−355.3%−71.8%
FY20−1676.2%−62.2%
FY19-−46.2%